F16.21
Hallucinogen dependence, in remission
Clinical Classification Guidelines
Inclusion Terms
- Other hallucinogen use disorder, moderate, in early remission
- Other hallucinogen use disorder, moderate, in sustained remission
- Other hallucinogen use disorder, severe, in early remission
- Other hallucinogen use disorder, severe, in sustained remission
- Phencyclidine use disorder, moderate, in early remission
- Phencyclidine use disorder, moderate, in sustained remission
- Phencyclidine use disorder, severe, in early remission
- Phencyclidine use disorder, severe, in sustained remission
Medical Intelligence & Overview
The ICD-10 code F16.21 refers to a history of dependence on hallucinogens, now in remission. This condition involves prior issues with substances such as LSD, psilocybin, PCP, and other hallucinogenic drugs. Although the individual is no longer dependent, this history is important for healthcare providers to consider in ongoing health management and treatment planning.
Causes & Symptoms
Clinical Causes: Repeated use of hallucinogenic substances leading to psychological dependence Use of substances like LSD, psilocybin, mescaline, PCP, or other hallucinogens over a period Psychosocial factors including peer pressure, stress, or mental health disorders Availability and accessibility of these substances Underlying mental health conditions that may increase susceptibility
Key Symptoms: Past episodes of altered perception and hallucinations Cravings or a strong desire to use hallucinogens Difficulty controlling substance use previously Potential psychological issues such as anxiety or depression related to substance use history No current physical dependence symptoms due to remission
Diagnostic & Treatment
Diagnosis Path: Diagnosis is typically based on a comprehensive evaluation by a healthcare professional, including a detailed history of substance use, mental health assessment, and identification of past dependence episodes. The diagnosis of remission indicates that the individual has successfully ceased problematic use, but the history remains relevant for future care.
Treatment Protocols: Psychotherapy (such as cognitive-behavioral therapy) to reinforce coping mechanisms Participation in support groups for recovering substance users Monitoring for potential triggers or mental health issues Education about the risks of relapse Regular follow-up with healthcare providers
Clinical Advice & FAQs
Billing Guidance
Is F16.21 a billable ICD-10 code?
Yes, F16.21 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.21?
Clinical documentation must specify the nature of Hallucinogen dependence, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference